SCHEMBL1106717

SCHEMBL1106717

C=C1CC(C)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25472224 1.00
SCHEMBL1106722 0.74
SCHEMBL1106723 0.74
SCHEMBL12021992 0.71
SCHEMBL8398004 0.70
SCHEMBL13383282 0.69 CA1 (0.37)
SCHEMBL3412400 0.67
SCHEMBL78498 0.67
SCHEMBL25140654 0.67
SCHEMBL45956 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744816-B2 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease ESPERION THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230210800-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS INC (US) 2023-07-06 US disclosed
EP-2649160-B1 PROCESSES UTILIZING SOLVENT EXTRACTION EXXONMOBIL CHEMICAL PATENTS INC (US) 2022-03-16 EP disclosed
US-20180133177-A1 Treatment of NASH with Gemcabene NEUROBO PHARMACEUTICALS, INC. 2018-05-17 US disclosed
US-20180064671-A1 Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease GLAS AMERICAS LLC 2018-03-08 US disclosed
US-9855240-B2 Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2018-01-02 US disclosed
US-20170349516-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170172955-A1 Treatment of Mixed Dyslipidemia NEUROBO PHARMACEUTICALS, INC. 2017-06-22 US disclosed
CN-104011061-B As HCV rna replicon inhibitor 2 ', ' the methyl substituted nucleoside derivates of 4 ' difluoro 2 里博科学有限责任公司 2017-06-13 CN disclosed
US-9662307-B2 Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2017-05-30 US disclosed
US-20120225908-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2012-09-06 US disclosed
US-20120172337-A1 CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2012-07-05 US disclosed
US-20120135146-A1 METHODS OF FORMING TOPOGRAPHICAL FEATURES USING SEGREGATING POLYMER MIXTURES JSR CORPORATION (JP) 2012-05-31 US disclosed
US-20120129930-A1 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-8153690-B2 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management ESPERION THERAPEUTICS, INC. (US) 2012-04-10 US disclosed
US-20110003860-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2011-01-06 US disclosed
US-7449277-B2 Positive resist compositions and patterning process SHIN-ETSU CHEMICAL C., LTD (JP) 2008-11-11 US disclosed
US-20080261147-A1 Photoactive Compounds RAHMAN M DALIL 2008-10-23 US disclosed
US-7358408-B2 Photoactive compounds AZ ELECTRONIC MATERIALS USA CORP. (US) 2008-04-15 US disclosed
US-20080058542-A1 Photoactive Compounds RAHMAN M D 2008-03-06 US disclosed